Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448249 | 0.89 | MAPK1 (0.53) | MAPK1STK17ASTK17BEGFRKDR | |
| SCHEMBL3450615 | 0.85 | MAPK1 (0.46) | MAPK1STK17ASTK17BEGFRKDR | |
| SCHEMBL3449010 | 0.85 | CSNK2A1 (0.45) | MAPK1STK17ASTK17BEGFRABL1 | |
| SCHEMBL3449347 | 0.85 | MAPK1 (0.47) | MAPK1STK17ASTK17BEGFRKDR | |
| SCHEMBL3447505 | 0.84 | MAPK1 (0.49) | MAPK1STK17ASTK17BEGFRGRM4 | |
| SCHEMBL13310864 | 0.84 | MAPK1 (0.44) | MAPK1STK17ASTK17BEGFRKDR | |
| SCHEMBL3451056 | 0.83 | MAPK1 (0.42) | MAPK1STK17ASTK17BEGFRKDR | |
| SCHEMBL3426298 | 0.83 | MAPK1 (0.48) | MAPK1STK17ASTK17BEGFRGRM4 | |
| SCHEMBL3450301 | 0.83 | MAPK1 (0.43) | MAPK1STK17ASTK17BEGFRKDR | |
| SCHEMBL3448295 | 0.82 | MAPK1 (0.45) | MAPK1STK17ASTK17BEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | MAPK1 2905/4885STK17A 1984/4885STK17B 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.